Recombinant Human PVRIG Protein，His

PVRIG (Programmed Cell Death Protein 1 Ligand 2) is an immune checkpoint protein that plays a crucial role in the regulation of T-cell responses in the tumor microenvironment. Its expression is often upregulated in various cancers, contributing to immune evasion and tumor progression. Research on PVRIG's structure and function has gained momentum due to its potential as a therapeutic target for cancer immunotherapy. The understanding of PVRIG's mechanisms of action, particularly its interactions with receptors on T-cells, could pave the way for the development of novel immunomodulatory treatments. Furthermore, the recombinant production of PVRIG protein enables detailed biochemical studies and the exploration of its role in immune regulation. By generating and characterizing PVRIG recombinants, scientists aim to elucidate its binding affinities, signaling pathways, and overall impact on immune cell functionality. This research is critical not only for advancing our understanding of immune checkpoints but also for enhancing the efficacy of existing immunotherapies and potentially overcoming resistance mechanisms in cancer treatment. As the field progresses, targeting PVRIG in conjunction with other immune checkpoints may offer synergistic effects that could lead to more effective therapeutic strategies in oncology.